Every S-3 that Sensei Biotherapeutics, Inc. (SNSE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow SNSE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SNSE filings page.
Faeth Therapeutics, Inc. filed a shelf registration and prospectus supplement to offer up to $150,000,000 of common stock under a sales agreement with TD Securities (USA) LLC (TD Cowen) as an at-the-market program. Shares may be sold from time to time on Nasdaq at market prices and the company will receive net proceeds from sales.
The prospectus describes the securities that may be offered under the base shelf (common stock, preferred stock, debt securities and warrants), notes that PIKTOR is in ongoing clinical trials with topline Phase 2 data anticipated by year-end 2026, and discloses corporate and charter details including an outstanding Series B Non-Voting Convertible Preferred Stock balance of 501.899 shares convertible at 1,000 common shares per preferred share.
Sensei Biotherapeutics, Inc. amends a shelf registration to register 24,868,028 shares of Common Stock for resale by selling stockholders following its February 2026 acquisition of Faeth Therapeutics and a concurrent private placement.
The registration covers resale of shares issuable upon automatic conversion of Series B Preferred Stock (1,000:1 conversion) and certain warrant-related shares, and notes shareholder approval and an increase in authorized common shares to 300,000,000.
Sensei Biotherapeutics, Inc. is registering 24,868,028 shares of Common Stock for resale by selling stockholders under a shelf prospectus. The Resale Shares include 10,425,531 Merger Conversion Shares, 14,440,395 Private Placement Conversion Shares and 2,102 Warrant Conversion Shares. Conversion of the Series B Preferred Stock into Common Stock occurs at 1,000 shares per Series B share, but conversion and resale are subject to stockholder approvals described as the Conversion Proposal and the Authorized Share Proposal and to beneficial ownership limits set by preferred holders. The company will not receive proceeds from sales by the selling stockholders; the 2026 Private Placement raised approximately $200 million at $13,850 per Series B Preferred share. If approved by Nasdaq and stockholders, the company expects to change its name to Faeth Therapeutics, Inc. and list under the symbol FTH. The last reported sale price for Common Stock was $21.14 on May 31, 2026.
Sensei Biotherapeutics, Inc. has registered 24,868,028 shares of Common Stock for resale by selling stockholders under a shelf prospectus dated April 28, 2026. The registered shares consist of Merger Conversion Shares, Private Placement Conversion Shares and Warrant Conversion Shares related to the February 2026 Acquisition of Faeth Therapeutics and a concurrent private placement.
The company will not receive proceeds from Resale Shares; proceeds go to the selling stockholders. The registration covers shares issuable on conversion of Series B Non-Voting Convertible Preferred Stock and certain warrant conversions and is subject to stockholder approvals required by Nasdaq listing rules.